Eight years later, Bristol-Myers acquired Mead Johnson & Company, which was a leader in science-based infant and children's nutrition. Squibb, on the other hand, delved into cancer research ...

The Pediatric Antibiotics Market comprises specialized formulations of beta-lactams, macrolides, cephalosporins, and sulfonamides designed to treat bacterial infections in infants and children. These ...

Savers Value Village, Inc. (the "Company") , the largest for-profit thrift operator in the United States ("U.S.") and Canada for value priced pre-owned clothing, accessories and household goods, today ...

Ananthakrishnan, MD, an associate professor of medicine with Massachusetts General Hospital ... included relationships with AbbVie, Bristol-Myers-Squibb, CED Service GmbH, Celltrion Healthcare ...

Bristol-Myers Squibb will pay $350 million to the State of Hawaiʻi to resolve all state claims related to the prescription drug Plavix. The state will dismiss its case and release all related ...

2seventy bio, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has successfully completed a merger agreement with Bristol-Myers Squibb Company (NYSE:BMY). According to ...

Bristol Myers CEO Christopher Boerner advocates global cost-sharing for drug R&D and criticizes PBMs. Read nore here.

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom.